Trial Profile
Comparative clinical study of alilocumab (Praluent) and evorocumab (Repatha) for dyslipidemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2020
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 03 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Jan 2019 Status changed from not yet recruiting to recruiting.
- 29 Oct 2018 New trial record